Studies related to Blood Glucose and Berberine

Berberine In The Treatment Of Type 2 Diabetes Mellitus: A Systemic Review And Meta-analysis

Effect Decrease
Trial Design Meta analysis
Trial Length n/a
Number of Subjects 1068
Gender n/a
Notes for this study:
In diabetic patients, Berberine at 0.5-1.5g daily for an average period of 12 weeks was associated with minor to moderate improvements on all measured glucose and lipid parameters; rivalling oral hypoglycemics in potency

Treatment Of Type 2 Diabetes And Dyslipidemia With The Natural Plant Alkaloid Berberine

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 116
Gender Both Genders
Age Range 18-29, 30-44, 45-64
Body Types Overweight
Notes for this study:
Berberine in isolation at 1g for 3 months was able to reduce triglycerides and fasting glucose levels in type II diabetics. Total cholesterol and LDL also decreased, and an increase in glucose disposal rate was seen.

Insulin sensitivity showed a trend for improvement, but did not reach statistical significance.

Efficacy Of Berberine In Patients With Non-Alcoholic Fatty Liver Disease

Effect Decrease
Values -6.14 AUCglucose in glucose tolerance test for lifestyle interventions plus berberine versus -3.33 for lifestyle interventions alone
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 184
Gender Both Genders
Age Range 30-44, 45-64, 65+
Body Types Obese, Overweight
Notes for this study:
184 patients with nonalcoholic fatty liver disease were randomized to one of three arms for 16 weeks: lifestyle intervention alone, lifestyle interventions plus 15mg pioglitazone daily, or lifestyle interventions plus 0.5g berberine three times a day. Berberine plus lifestyle changes significantly improved liver fat content, BMI, HOMA-IR, total cholesterol, and triglycerides significantly more than lifestyle interventions alone. The berberine group tended to have minor digestive issues that tended to resolve 2 weeks into the study.

Effect Of Berberine Administration On Metabolic Syndrome, Insulin Sensitivity, And Insulin Secretion

Effect Decrease
Values AUC glucose: 1182.1mmol/L placebo vs. 1069.5±172.4mmol/L berberine.
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 24
Gender Both Genders
Body Types Obese, Overweight
Notes for this study:
24 people with metabolic syndrome were randomized to placebo or 0.5g berberine three times a day for three months. Decrease in waist circumference in females only, systolic blood pressure, triglycerides, area under the curve of glucose and insulin, and Matsuda index were all seen to be significant in the berberine group versus placebo.